非贴壁微球体培养法分离T-淋巴细胞瘤干细胞及鉴定

通过非贴壁微球体无血清培养法,体外构建并鉴定了T-淋巴细胞瘤干细胞。采用细胞球悬浮培养方法富集T-淋巴细胞肿瘤干细胞,利用抑制分化作用的抑制剂CHIR99021和PD173074(2i)进行肿瘤干细胞的筛选,采用RT-PCR法检测Sox2、Oct4、Nanog、Klf4、Bmi1、C-Myc干细胞特征基因的表达,进一步采用Western blot验证Oct4蛋白水平表达,流式细胞术分析CD34、CD44抗体表达情况,用PI检测细胞周期,用CFSE观察细胞增殖能力,并将富集的T-淋巴细胞肿瘤干细胞进行裸鼠异体移植实验。在细胞球悬浮培养法基础上,利用具有抑制分化作用的抑制剂CHIR99021和PD173074,成功富集出Hut-102干细胞球。经RT-PCR鉴定,Hut-102干细胞球的其干细胞特征基因Sox2、Oct4、Nanog、Klf4、Bmi1、C-Myc表达均显著性高于Hut-102细胞并且高表达Oct4蛋白;经流式细胞术分析CD34、CD44抗体表达,有74.20%的Hut-102干细胞球表现为CD34+,有90.82%的Hut-102干细胞球表现为CD44+,证明抑制分化药物应用于细胞球悬浮培养方法中,能够有效富集出具有CD34+CD44+表型特征的Hut-102干细胞球;用PI检测细胞周期,富集的Hut-102干细胞球中处于G1/G0期的细胞为64%,处于S期的细胞为30.56%,表明该细胞暂不增殖或处于休止状态;用CFSE检测到富集的Hut-102干细胞球分化增殖能力显著高于Hut-102细胞。在NON/SCID裸鼠中,分别移植Hut-102细胞球和Hut-102细胞,结果显示,前者检测到67.74%±5.32%的淋巴细胞表达Hut-102细胞特异性标记物(CD3),而后者的裸鼠中未检测到,说明Hut102细胞球在NON/SCID裸鼠体内表现了T-淋巴细胞肿瘤干细胞特点和移植能力。首次在传统的非黏连微球体无血清培养法中加入两种抑制剂(CHIR99021和PD173074),富集出大量的微球体,通过干细胞特征鉴定及裸鼠移植实验,证明Hut-102细胞球具有T-淋巴细胞肿瘤干细胞特性。     

miR-382-5p通过靶基因PTEN阻滞NB4细胞分化

该文主要研究在急性早幼粒细胞白血病NB4细胞中, miR-382-5p通过调控靶基因PTEN(phosphatase and tensin homologue)抑制了全反式维甲酸(all-trans retinoic acid, ATRA)诱导的急性早幼粒细胞分化。我们运用ATRA(1μmol/L)诱导细胞分化; Western blot检测PTEN及髓系分化标志物CD11b的蛋白质水平;实时荧光定量PCR检测miR-382-5p的表达水平;过表达PTEN的慢病毒载体分别感染NB4细胞和HL-60、THP-1细胞;脂质体转染miR-382-5p的模拟剂(mimics)和特异性抑制剂(inhibitors)NB4细胞。结果显示, PTEN促进ATRA诱导的NB4细胞分化,而在HL-60和THP-1细胞中并无明显促分化效应。NB4细胞中,脂质体转染miR-382-5p mimics在mRNA和蛋白水平均抑制了PTEN的表达,并且抑制了ATRA诱导的分化;转染miR-382-5p inhibitors则恢复了PTEN表达,同时促进了ATRA诱导的急性早幼粒细胞NB4细胞的分化。该文结果提示, miR-382-5p靶向抑制了PTEN的表达从而抑制ATRA诱导的NB4细胞分化。     

CD147对白血病细胞U937生长和肿瘤形成的影响

目的：研究CD147对白血病细胞U937生长和肿瘤形成的影响。方法：分别采用脂多糖（LPS）或CD147单克隆抗体处理U937细胞;用RT-PCR和流式细胞术分别在mRNA和蛋白水平检测各组中CD147的表达情况;用流式细胞术检测在LtX3和CD147单克隆抗体作用下U937细胞周期的变化;用MTT法对各组细胞的生长状况进行分析;将细胞经皮下接种于裸鼠体内,对各组间肿瘤生长速度、肿瘤体积及裸鼠存活时间进行统计分析。结果：LPS在体外能够诱导自血病细胞U937表面CD147的表达,同时细胞增殖旺盛,但细胞凋亡数增加;使用CD147抗体阻断CD147后,能够将细胞周期阻断在G0／G1期,细胞活力下降,并诱导细胞凋亡;CD147抗体体外预处理能够抑制U937细胞在裸鼠体内的生长,使小鼠存活时间延长。结论：LPS可诱导U937细胞表面CD147分子表达增加,从而促进U937细胞的生长和肿瘤形成。     

CD11b/DNA双参数流式细胞术检测HL-60细胞分化的细胞周期

目的采用双参数流式细胞术研究全反式维甲酸(alltransretinoidacid,ATRA)诱导人类急性早幼粒白血病细胞HL-60细胞分化的细胞周期。方法HL-60细胞经分化诱导剂ATRA(终浓度为1μmol/L)诱导不同时间点后,利用CD11b/DNA双参数流式细胞术同时检测分化细胞表面抗原CD11b的表达及分化细胞DNA含量。结果HL-60细胞经ATRA诱导后,细胞表面分化抗原CD11b表达明显升高,细胞阻滞于G0/G1期,且CD11b阳性细胞主要位于G0/G1期。结论CD11b/DNA双参数流式细胞术能简便,快速,直观地检测细胞分化的细胞周期。     

TGF-β信号通路抑制剂LY364947对急性髓系白血病细胞增殖、凋亡和侵袭的影响

该文旨在探讨抑制TGF-β信号通路对人急性髓系白血病(acute myeloid leukemia,AML)细胞体外增殖、凋亡和侵袭能力的影响。使用不同浓度TGF-β信号通路抑制剂LY364947处理AML细胞系(KG1a、OCI-AML3)后,采用CCK-8实验检测细胞体外增殖能力;流式细胞术检测细胞周期分布及凋亡情况; Western blot检测细胞周期调控因子Cyclin D1/p21、凋亡相关蛋白Bcl-2/Bax以及上皮细胞间质转化相关蛋白E-cadherin、N-cadherin和vimentin的表达; Transwell实验测定AML细胞迁移及侵袭能力的变化。结果显示:LY364947作用后,白血病细胞生长明显受抑制;细胞周期阻滞在G1期,伴有Cyclin D1表达下调和p21表达上调;细胞凋亡率增加,同时细胞抗凋亡蛋白Bcl-2的表达水平下降,促凋亡蛋白Bax表达增高;细胞体外迁移和侵袭能力减弱。此外, E-cadherin表达增高, N-cadherin和vimentin表达下降。该研究结果提示,抑制TGF-β信号通路能够抑制白血病细胞的体外增殖,诱导细胞凋亡,降低细胞迁移及侵袭能力。     

丁酸钠和丙酸钠对工程CHO细胞生长代谢和嵌合抗体表达的影响

抗p185erbB-2基因工程抗体是一种有潜力的抗肿瘤药物。以稳定表达抗p185嵌合抗体的重组工程CHO细胞株为对象,分别用不同浓度丁酸钠(0~2mmol/L)和丙酸钠(0~10mmol/L)对处在对数生长期的细胞进行处理,在连续5d的培养过程中,每隔24h取样测活细胞数量,并用ELISA检测上清中抗体含量,5d后结束培养用FACS检测细胞周期。同时还用丁酸钠和丙酸钠处理长至90%满度的细胞,然后每隔12h取样一次检测葡萄糖和乳酸的含量。结果表明丁酸钠和丙酸钠可以有效地提高嵌合抗体在工程CHO细胞中的表达,表达量最高时可达58.3~59.6mg/L,是对照组的1.5倍。同时抑制细胞生长和阻断细胞周期在G1期,并且可减少培养过程中葡萄糖的消耗和乳酸的生成。和丁酸钠相比,丙酸钠具有较小的细胞毒性,是一种有潜力的替代品。     

未分化和分化足细胞生物学性状及相关结构蛋白表达的变化

体外33℃许可条件下培乔由H-2Kb-tsA58转基因小鼠所建立的禾分化足细肥系,开在37℃非许可条件下诱导其分化.观察足细胞分化后形态学改变;MTT法测定细胞的生长曲线;红色荧光染料PKH-26标记足细胞,追踪其在子代细胞中的分布,检测细胞增殖能力;流式细胞仪检测细胞周期的改变;Western印迹检测足细胞相关蛋白CD2AP、α-actinin和足细胞分化相关蛋白nephrin的表达;免疫荧光结合激光共聚焦方法检测CD2AP、nephrin,α-actinin、F-肌动蛋白和微管蛋白的表达变化.结果显示:与未分化足细胞相比,分化足细胞形态发生改变,生长速度减慢,增殖能力下降:细胞周期表现为G0/G1期细胞比例的增多和S期及G2/M期的细胞比例下降;CD2AP、neDhrin和α-actinin的表达明显增高;CD2AP、nephrin、α-actinin、F-肌动蛋白和微管蛋白在表达分布上均发生明显的改变.以上结果表明,足细胞分化后生物学性状明显发生改变,细胞骨架重新分布:CD2AP、nephrin、α-actinin、F-肌动蛋白和微管蛋白均在足细胞的分化过程中发挥重要作用.     

丙戊酸钠抑制A549细胞生长

目的研究丙戊酸钠对肺癌A549细胞增殖和细胞周期的影响。方法MTT检测生长抑制,流式细胞仪检测细胞周期和凋亡,Western blot检测p21WAF1/CIP1蛋白表达。结果丙戊酸钠以剂量依赖性方式抑制A549细胞生长;丙戊酸钠上调G0/G1期比例,下调S期和G2/M期,不影响细胞凋亡;丙戊酸钠上调p21WAF1/CIP1蛋白表达。结论丙戊酸钠上调p21WAF1/CIP1表达,使细胞阻滞于G0/G1期,抑制A549细胞生长。     

重组肌肉抑制素功能分析及其对鸡肌肉发育的抑制作用

肌肉抑制素 (myostatin)为TGF β超家族成员 ,具有典型的TGF β家族成员特有的分子结构与功能。为了深入阐明肌肉抑制素的作用机制 ,研究了重组肌肉抑制素蛋白对鸡胚成肌细胞和小鼠C2 C1 2 成肌细胞增殖与分化的作用 ,同时制备了肌肉抑制素特异性抗体。实验结果表明 ,重组肌肉抑制素对于成肌细胞的增殖过程具有极强的抑制作用 ,主要表现为抑制细胞周期由G1 期向S期的过渡 ,细胞生长速度显著变慢 ;同时重组肌肉抑制素也抑制成肌细胞分化为多核的融合肌管细胞 ,抑制肌肉分化标志myogenin和MHC的表达。由重组蛋白质制备的抗体能够特异性地识别人、小鼠、大鼠和鸡肌肉组织的内源肌肉抑制素。此外 ,通过免疫荧光技术还证实 ,肌肉抑制素主要定位于胞液中     

低分子量透明质酸寡糖片段介导内皮细胞增殖的信号通路

为研究低分子量透明质酸寡糖片段(hyaluronan oligosaccharides, o-HA)对血管内皮细胞生长与迁移的影响,及透明质酸（hyaluronan,HA）受体（CD44与RHAMM）在此过程中的作用,首先通过细胞计数、MTT实验、细胞周期分布及单层细胞损伤模型修复实验,观察o-HA对血管内皮细胞（猪髂总动脉内皮细胞,porcine vascular endothelial cell line,PIEC）增殖及创伤愈合的影响．结果显示,o-HA明显促进血管内皮细胞生长,并且能够促进内皮细胞向创伤区迁移.蛋白质免疫印迹分析证明,o-HA作用于PIECs后,细胞Src激酶、ERK-1/2的磷酸化程度增强,c-Myc蛋白、周期蛋白D1表达水平增高.Src 激酶特异性的化学抑制剂PP2可轻度抑制ERK-1/2磷酸化;进而通过抗-CD44与抗-RHAMM抗体分别预先封闭细胞表面相应的特异性受体位点后,再用o-HA刺激细胞,探讨HA受体在o-HA介导PIECs信号传导过程中的作用．结果显示,抗CD44抗体不能抑制o-HA介导的ERK-1/2磷酸化;而抗RHAMM抗体可轻度抑制o-HA介导的ERK-1/2磷酸化．结果提示,o-HA具有促进血管内皮细胞增殖及创伤愈合的作用,其机制可能是通过血管内皮细胞表面受体RHAMM实现的.该作用可能通过激活Src激酶及细胞内MAPK（ERK-1/2）信号通路,启动早期反应基因转录,诱使c-Myc蛋白高表达,从而促进血管内皮细胞生长．该作用也可能与上调细胞周期蛋白 D1的表达有关．     

Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression

T cells can be activated to proliferate by antibodies to the T cell antigen receptor or the molecularly associated CD3 complex if monocytes are present. We have shown previously that monoclonal antibodies to the human T cell differentiation antigens CD5 (Tp67) and Tp44 each augment and prolong proliferative responses of anti-CD3-activated T cells, even in the absence of monocytes. Here we show that the functional and biochemical mechanisms of CD5 and Tp44 signal transmission are distinct. T cell proliferation is suppressed by agents that increase the concentration of intracellular cAMP. We found that antibody binding to the Tp44 surface molecule overcomes this suppression, whereas antibody binding to CD5 does not, indicating that ligand-Tp44 interaction changes T cell sensitivity to cAMP-mediated growth inhibition. The ability of anti-CD3, anti-Tp44, and anti-CD5 monoclonal antibodies to directly alter cyclic nucleotide levels in the Jurkat T cell line was examined. Anti-CD3 alone caused a rapid four- to sixfold increase in cAMP levels, but did not affect cGMP levels. However, anti-Tp44 and anti-CD5 each caused a rapid three- to fourfold increase in cGMP levels without affecting cAMP levels. In other experiments, cytoplasmic free calcium levels were measured in resting T cells after CD5 or Tp44 stimulation by using the dye indo-1 and flow cytometry. This sensitive method showed that anti-CD5 alone caused an increase in cytoplasmic calcium free levels within 3 min of antibody addition, whereas anti-Tp44 had no effect. Finally, anti-Tp44 and IL 1 each augmented proliferation of phorbol ester-stimulated lymphocytes, whereas anti-CD5 did not. The effects of IL 1 and Tp44 could be further distinguished in that the effect of anti-Tp44 was resistant to inhibition by dBcAMP whereas IL 1 was not. These data suggest that the receptor function of both Tp44 and CD5 involves changes in cyclic nucleotides levels, and that the mechanism by which anti-Tp44 and anti-CD5 antibodies affect T cell proliferative responses may be related to their selective effects on cGMP levels and cytoplasmic calcium concentrations.     

Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia.

Blockage in myeloid differentiation characterizes acute myeloid leukemia (AML); the stage of the blockage defines distinct AML subtypes (AML1/2 to AML5). Differentiation therapy in AML has recently raised interest because the survival of AML3 patients has been greatly improved using the differentiating agent retinoic acid. However, this molecule is ineffective in other AML subtypes. The CD44 surface antigen, on leukemic blasts from most AML patients, is involved in myeloid differentiation. Here, we report that ligation of CD44 with specific anti-CD44 monoclonal antibodies or with hyaluronan, its natural ligand, can reverse myeloid differentiation blockage in AML1/2 to AML5 subtypes. The differentiation of AML blasts was evidenced by the ability to produce oxidative bursts, the expression of lineage antigens and cytological modifications, all specific to normal differentiated myeloid cells. These results indicate new possibilities for the development of CD44-targeted differentiation therapy in the AML1/2 to AML5 subtypes.     

Exogenous glutamine requirement is confined to late events of T cell activation

Glutamine is required for the proliferation of lymphocytes, but quantitative effects on discrete steps of activation remain unknown to date. Therefore the influence of glutamine (range: 0 mM–1 mM) on the in vitro response of human peripheral blood mononuclear cells (PBMC) to a mitogenic anti-CD3 monoclonal antibody (mAb) was investigated. Expression of surface activation markers by flow cytometry, presence of mRNA of cytokine genes by polymerase chain reaction, release of cytokines by ELISA, and entering into the cell cycle by flow cytometry were sequentially analyzed. Proliferation was measured by a ³H-thymidine incorporation assay. mRNA coding for IL-2, IL-2 receptor, IL-4, IL-5, GM-CSF, and IFN-γ was detectable independently from exogenous glutamine provision; expression of the cell surface activation marker CD69 was also glutamine independent. In contrast, later activation events including the expression of the surface activation markers CD25, CD45RO, and CD71 as well as the production of IFN-γ were found to require exogenous glutamine supply. In contrast, production of TNF-α could be observed in the absence of glutamine and was increased to a limited extent by exogenous glutamine. The overall lymphocyte response as reflected by entering into the cell cycle and proliferation was directly correlated with the glutamine concentration of the culture medium. Efficient progression through the cell cycle was found to require at least 0.5 mM glutamine and an increase in glutamine concentration from 0.1 mM to 1 mM enhanced proliferation by 50%. These results were supported by data obtained following anti-CD3 stimulation of a CD4⁺ T cell clone. Altogether, these data underline that a complete cellular immune response depends on an exogenous glutamine supply. Regarding glutamine requirements, they define early, glutamine-independent and late, glutamine-dependent lymphocyte activation stages.     

An easy method to detect the kinetics of CD44 antibody and its receptors on B16 cells using atomic force microscopy

CD44 is the principle cell surface receptor for the extracellular matrix. The altered expression or dysfunction of CD44 proteins contributes to numerous pathological processes. Therefore, it is very necessary to detect the distribution and density of CD44 proteins on cell surface. In this paper, the unbinding force between the tip of an atomic force microscope modified with anti-human CD44 antibody (a kind of CD44 pathway ligation proteins, currently used to induce the apoptosis of some types of tumors) and B16 (human melanoma cell line) cells was measured. The results indicated that the distribution of CD44 was nonuniform and represented clusters on B16 cell surface. And, the data of kinetics of CD44 antibody-antigen binding experiments indicated that the CD44 signal pathway in B16 cells could be blocked by anti-CD44 monoclonal antibody. This methodology can be extended to the evaluation and screening of molecular targeted drugs for pharmacological use.     

A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes

We previously described a cell surface antigen, termed Tp44, detected by monoclonal antibody 9.3 on approximately 80% of mature human T lymphocytes. Analysis by SDS-polyacrylamide gel electrophoresis and isoelectric focusing demonstrated that this antigen consists of two identical 44 kilodalton glycopeptides that form a disulfide-linked homodimer. Competitive binding experiments showed that antibody 9.3 and an anti-CD3 antibody (64.1) recognize distinct antigenic determinants; furthermore, the binding of antibody 9.3 was unaffected by prior modulation of CD3. Thus, Tp44 has no detectable cell surface association with CD3. By itself, antibody 9.3 had no detectable effect on either IL 2 receptor expression or IL 2 release, and did not cause T cell proliferation even when monocytes were present and exogenous IL 2 was provided, indicating that binding of antibody 9.3 does not provide a primary signal for T cell activation. However, the proliferative responses of T lymphocytes activated by phytohemagglutinin, concanavalin A, or an anti-CD3 monoclonal antibody were strikingly enhanced in the presence of antibody 9.3, an effect associated with increased IL 2 receptor expression and increased IL 2 secretion. Antibody 9.3 enabled anti-CD3-Sepharose-activated T cells and anti-CD3 antibody-activated Jurkat cells to release IL 2 in the absence of monocytes. Fab fragments of antibody 9.3 had no effect on anti-CD3-induced IL 2 release by Jurkat cells, whereas F(ab')2 fragments had activity comparable to that of unmodified antibody, indicating that bivalent binding of Tp44 molecules is required for IL 2 secretion. Together, these results suggest that TP44 may function as a receptor for accessory signals in the activation of T cells.     

Ligation or cross-linking of CD40 has different effects on AGS gastric cancer cells

A gastric cancer (GC) cell line, AGS, has high-level expression of CD40, a tumor necrosis factor receptor (TNFR) family member. CD40 is present on the surfaces of a large variety of cells, including B cells, endothelial cells, dendritic cells and some carcinoma cells, and delivers signals regulating diverse cellular responses, such as proliferation, differentiation, growth suppression, and cell death. In this research, we studied the effects of different forms of CD40 stimulation on AGS cells by flow cytometry, Western blotting and siRNA transfection. We found that different forms of CD40 stimulation, either recombinant soluble CD40L (sCD40L, ligation) or agonist anti-CD40 antibody (cross-linking), induced different effects in AGS gastric cancer cells, proliferation or apoptosis. We also showed that VEGF provided a significant contribution to sCD40L-induced proliferation, while agonist anti-CD40 antibody induced GADD45 upregulation and promoted apoptosis.     

Comparison of Humanized IgG and FvFc Anti-CD3 Monoclonal Antibodies Expressed in CHO Cells

Two humanized monoclonal antibody constructs bearing the same variable regions of an anti-CD3 monoclonal antibody, whole IgG and FvFc, were expressed in CHO cells. Random and site-specific integration were used resulting in similar expression levels. The transfectants were selected with appropriate selection agent, and the surviving cells were plated in semi-solid medium for capture with FITC-conjugated anti-human IG antibody and picked with the robotic ClonePix FL. Conditioned media from selected clones were purified by affinity chromatography and characterized by SDS-PAGE, Western-blot, SEC-HPLC, and isoelectric focusing. Binding to the target present in healthy human mononuclear cells was assessed by flow cytometry, as well as by competition between the two constructs and the original murine monoclonal antibody. The humanized constructs were not able to dislodge the murine antibody while the murine anti-CD3 antibody could dislodge around 20% of the FvFc or IgG humanized versions. Further in vitro and in vivo pre-clinical analyses will be carried out to verify the ability of the humanized versions to demonstrate the immunoregulatory profile required for a humanized anti-CD3 monoclonal antibody.     

Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation

The ability of acute myelogenous leukemia (AML) blasts to mediate costimulatory signals during T lymphocyte activation was investigated in an experimental model where monoclonal T cell populations were stimulated with standardized activation signals (anti-CD3, anti-CD2, and anti-CD28 monoclonal antibodies and phytohemagglutinin). Proliferative T cell responses were detected for all AML patients (n = 16) when irradiated leukemia blasts were used as accessory cells during activation. T cell cytokine release was also observed for all patients when nonirradiated AML accessory cells were used, and for most patients a broad cytokine response (interleukin (IL) 2, IL4, IL10, IL13, and interferon-gamma) was detected. However, both T cell proliferation and cytokine release showed a wide variation among AML patients, and T cell responsiveness was in addition dependent both on the nature of the activation signal and on differences between individual T cell clones. The accessory cell function of AML blasts showed no correlation with the release of any single immunomodulatory soluble mediator (IL1beta, IL6, TNF-alpha, soluble IL2 receptors) or the expression of any particular adhesion/costimulatory membrane molecule (CD54, CD58, CD80, and CD86) by the blasts. However, blocking studies with anti-CD58 and anti-CD80/86 monoclonal antibodies demonstrated that both pathways can be involved when AML blasts are used as accessory cells, but the relative importance and the final effects of signaling through these pathways differ between AML populations. Although there is a wide interpatient variation, we conclude that for a majority of patients the native AML blasts can mediate adequate costimulatory signals needed for accessory cell-dependent T cell activation.